Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Post-Market Plan Gains Support, But Many Details Still Lacking

This article was originally published in The Gray Sheet

Executive Summary

A diverse set of stakeholders backed FDA’s new proposed national post-market surveillance plan during a series of public meetings last week, but participants warned “the devil is in the details.”


Related Content

Planning Board Urges FDA To Launch Postmarket Incubator Project
Planning Board Proposes Postmarket Device Surveillance Timeline
Regulatory Briefs: MAUDE Replacement; Electronic Source Data Guidance; Social Media Monitoring
FDA To Issue Final Device Post-Market Surveillance Plan In February
FDA MDEpiNet Panel: Device Surveillance Balancing Act
Leveraging Registries: A Next Step In National Post-Market Plan
FDA Unveils Plan To Strengthen Device Post-Market Surveillance
FDA’s UDI Draft Rule Details Device Marking, Database Submission Mandates
Midwest Hospitals Prepare For Stent Unique-Device-Identifier Demo
With eMDRs On The Way, Many Firms Are Updating Complaint Handling Systems





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts